For research use only, not for therapeutic use.
(E)-3-(2,3,4,5-Tetrabromophenyl)acrylic acid（Cat No.:R041830）is a synthetic compound featuring a highly brominated aromatic moiety attached to an acrylic acid backbone. This compound has garnered interest for its potential applications in organic synthesis and materials science, particularly in the development of novel polymers and bioactive materials. The presence of multiple bromine atoms enhances its chemical reactivity and may impart unique physical properties, such as increased stability and solubility in organic solvents. Research is ongoing to explore its biological activities, including possible antitumor and antimicrobial properties, expanding its utility in various scientific fields.
| Catalog Number | R041830 |
| CAS Number | 934358-00-6 |
| Synonyms | (2E)-3-(2,3,4,5-Tetrabromophenyl)-2-propenoic Acid; TBCA |
| Molecular Formula | C9H4Br4O2 |
| Purity | ≥95% |
| Target | CK2 |
| Solubility | Soluble in DMSO |
| Storage | Store at -20°C |
| IUPAC Name | (E)-3-(2,3,4,5-tetrabromophenyl)prop-2-enoic acid |
| InChI | InChI=1S/C9H4Br4O2/c10-5-3-4(1-2-6(14)15)7(11)9(13)8(5)12/h1-3H,(H,14,15)/b2-1+ |
| InChIKey | SVJQCVOKYJWUBC-OWOJBTEDSA-N |
| SMILES | C1=C(C(=C(C(=C1Br)Br)Br)Br)/C=C/C(=O)O |
| Reference | </br>1: Lee HR, Shin HK, Park SY, Kim HY, Lee WS, Rhim BY, Hong KW, Kim CD. Attenuation of β-amyloid-induced tauopathy via activation of CK2α/SIRT1: Targeting for cilostazol. J Neurosci Res. 2014 Feb;92(2):206-17. doi: 10.1002/jnr.23310. Epub 2013 Nov 19. PubMed PMID: 24254769.</br>2: Ryu SY, Kim S. Evaluation of CK2 inhibitor (E)-3-(2,3,4,5-tetrabromophenyl)acrylic acid (TBCA) in regulation of platelet function. Eur J Pharmacol. 2013 Nov 15;720(1-3):391-400. doi: 10.1016/j.ejphar.2013.09.064. Epub 2013 Oct 15. PubMed PMID: 24140231.</br>3: Lee HR, Park SY, Kim HY, Shin HK, Lee WS, Rhim BY, Hong KW, Kim CD. Protection by cilostazol against amyloid-β(1-40)-induced suppression of viability and neurite elongation through activation of CK2α in HT22 mouse hippocampal cells. J Neurosci Res. 2012 Aug;90(8):1566-76. doi: 10.1002/jnr.23037. Epub 2012 Mar 16. PubMed PMID: 22422579.</br>4: Yao K, Youn H, Gao X, Huang B, Zhou F, Li B, Han H. Casein kinase 2 inhibition attenuates androgen receptor function and cell proliferation in prostate cancer cells. Prostate. 2012 Sep 15;72(13):1423-30. doi: 10.1002/pros.22493. Epub 2012 Jan 30. PubMed PMID: 22290244.</br>5: Kim GS, Jung JE, Narasimhan P, Sakata H, Yoshioka H, Song YS, Okami N, Chan PH. Release of mitochondrial apoptogenic factors and cell death are mediated by CK2 and NADPH oxidase. J Cereb Blood Flow Metab. 2012 Apr;32(4):720-30. doi: 10.1038/jcbfm.2011.176. Epub 2011 Dec 7. PubMed PMID: 22146192; PubMed Central PMCID: PMC3318149.</br>6: Kramerov AA, Golub AG, Bdzhola VG, Yarmoluk SM, Ahmed K, Bretner M, Ljubimov AV. Treatment of cultured human astrocytes and vascular endothelial cells with protein kinase CK2 inhibitors induces early changes in cell shape and cytoskeleton. Mol Cell Biochem. 2011 Mar;349(1-2):125-37. doi: 10.1007/s11010-010-0667-3. Epub 2010 Dec 2. PubMed PMID: 21125314; PubMed Central PMCID: PMC3426611.</br>7: Pagano MA, Poletto G, Di Maira G, Cozza G, Ruzzene M, Sarno S, Bain J, Elliott M, Moro S, Zagotto G, Meggio F, Pinna LA. Tetrabromocinnamic acid (TBCA) and related compounds represent a new class of specific protein kinase CK2 inhibitors. Chembiochem. 2007 Jan 2;8(1):129-39. PubMed PMID: 17133643.</br> |
